SCIENCE BEHIND CT1
The application of adipose stem cells as a therapeutic product is the result of years of research and development. In recent years, adipose stem cells (ADSCs) have gained notoriety since its initial discovery in 2001. Since then, the ADSC has become the most popular adult stem cells due to its ease of harvest and ADSC’s ability to differentiate into multiple lineages. Since 2005, VetCell Therapeutics (VCT) has studied the use of adipose tissue in regenerative medicine and has published numerous manuscripts on the topic. Most of the early work was focused on mouse adipose stem cells and the findings are being applied for use in veterinarian medicine.
A large area of need in veterinary medicine is the treatment of osteoarthritis, which is common in animals as they age. Routine treatment of this ailment is with anti-inflammatory drugs or with surgical procedures.
Two of VCT’s publications highlight the use of a subpopulation of ADSCs which were derived from animal and human sources. These cells were isolated, expanded and differentiated into osteogenic, chonrdogenic and adipogenic lineages. These cells were also placed into a wound healing model and showed improved healing abilities of the skin’s dermal layers. These cells were also used in a project with a bone scaffolding unit. In an animal model, the transplanted cells mixed with the bone scaffold material differentiated into chondrogenic type cells and started to develop into mature chondrocytes.
VCT has worked on projects aimed at using adipose tissue as a source material to treat osteoarthritis. Our data, along with other publications, suggest that adipose tissue may be a reliable source for cells that can be used to treat bone and cartilage conditions as well as other indications. The need for an efficient treatment is desired for pets diagnosed with arthritis or other osteogenic conditions.
VetCell Therapeutics has numerous patents issued in the United States, Europe, Asia and Australia. The company also has filed patents focused on innovative use of stem cells in regenerative medicine. One of the many goals has been to develop intellectual property to protect the concepts of cell-based therapies and to strengthen the ability for success with cell based treatments
1- Zuk P., Zhu M., Mizuno H., et al., Tissue Engineering, vol. 7, no. 2, pp 211–228, 2001
2- Zuk P., ISRN Stem Cells Volume 2013 Article ID 713959
3- Guercio A., Di Marco P., Casella S., et al, Cell Biology Int, vol 36, (2), pp 189–194, 2012
4- Lindroos B, Suuronen R, Miettinen S., Stem Cell Rev. Jun 7, (2) pp 269-91, 2011
5- Lin F., Kidney International vol 82, pp 731–733, 2012
6- Ha S., Ahn S., Kim S., et al., J Biomed Opt. vol 19(5), 2014